Jacob sands

Tackling the toughest cases in lung cancer — from small-cell transformation and NUT carcinoma to brain mets in driver-negative NSCLC and beyond. The Clinical Challenges session at #TexasLung26 is moderated by Dr. @sands_jacob and features an all-star panel: Drs. Carl Gay, Paul Paik, Sarah Goldberg, Melissa Crawley, @LealTiciana, @JhanelleGray, and Andrew Shaw. Don't miss the 2-Day CE-Accredited conference! Check out the full agenda and register for FREE today with code FREECME: utm.rocks/tlcagenda April 9–11 | ACL Live, Austin, TX #ThoracicOncology #LungCancer #MedEd

Results of OSI plus DATODXD after PD on OSI are worth pursuing. Nice results although a small study. Needs confirmation.

IDEO Xchange: In DeLLphi‑304, tarlatamab beat chemo in 2L SCLC(OS 13.6 vs 8.3 mo; HR 0.60) with mostly low‑grade CRS/ICANS—but requires early monitoring infrastructure. Should it be immediate 2L SOC?

IDEO Xchange: After ADRIATIC showed a major OS improvement (median 55.9 vs 33.4 months, HR 0.73) and benefit regardless of PCI subgrouping, what should happen to prophylactic cranial irradiation in LS‑SCLC?

IDEO Xchange: With final 5‑yr OS now positive for neoadjuvant nivo+chemo in resectable NSCLC (65% vs 55% alive at 5 yrs),should chemo‑IO be the default approach for eligible stage II–III?

IDEO Xchange: A stage IIa NSCLC patient is presented to your tumorboard with PD-L1>25% (NGS pending). What would you recommend as the next step?

IDEO Xchange: In resectable NSCLC, which clinical factors most often lead you to use a perioperative chemo‑IO approach rather than neoadjuvant IO/chemo alone?

IDEO Xchange: How important is the availability of subsequent treatment options to your 1L EGFR-mutated mNSCLC treatment decision?

@IDEOlogyHealth Others commented: VTE, time in infusion room, financial (copay)

IDEO Xchange: In your experience, which treatment-associated adverse event in EGFR-mutated mNSCLC most negatively impacts patient quality of life?

Exciting to see another example of the value of targeted therapy!

Clinical trial now enrolling. @sands_jacob of @DanaFarber leads @ALLIANCE_org A081801 (ALCHEMIST Chemo-IO) testing if adding #immunotherapy to #chemotherapy after surgery improves survival in non-small cell #lungcancer. Learn more: bit.ly/Alliance-A0818… #NCI #NCTN #LCSM

This is the table we’ve used (common AEs, black📦warnings, & dose⬇️) during our ToxCheck 🗣️ on ADCs in #LungCancer with @sands_jacob: 1. TDXd: 🫁, Nausea, fatigue 2. DatoDXd: Stomatitis, dry 👀, 🫁 3. TelisoV: Neuropathy #OncTwitter #MedTwitter #lcsm @OncoAlert @OncUpdates

ToxCheck: AEs for ADCs approved in Lung Cancer & how to manage them with @sands_jacob: ✅ TDXd: HER2+ ✅ DatoDXd: EGFR+ ✅ TelisoV: C-MET Full 🗣️: ⭐️ oncbrothers.com/toxcheck-adclu… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates @OncoAlert #lcsm

ToxCheck: AEs for ROS1 inhibitors & how to manage them when treating ROS1 fusion positive NSCLC w/ @Latinamd ✅ Crizotinib ✅ Enterectinib ✅ Repotrectinib ✅ Taletrectinib Full 🗣️: ⭐️ oncbrothers.com/ros1-toxcheck-… ⭐️ Also on “Oncology Brothers” podcast #OncTwitter @OncUpdates

@M_Torasawa Your presentation was excellent! I’m so grateful to have been able to see it. Thank you. 🙏🏻

Highlight of my #JLCS25 day2 Had the honor of speaking as a symposist on T-cell engagers. Grateful to share the session with Prof @sands_jacob , who gave an outstanding lecture. I’ll keep working hard so that I can continue to present on big stages like this in the years to come 😌

@DrZ_84 @LuisPaz_Ares So fun seeing you! 🙏🏻

IMforte & DeLLPhi-304 updates on #SCLC this evening At #ESMO25 • Lurbi+Atezo improved PFS/OS & reduced liver progression, more pts relapsed in brain (4.3 vs 2.8 mo → mainly extra-CNS benefit). ••Tarlatamab confirmed as new 2L SoC with better PFS, OS, regardless of PD-L1 or CFI

🚨 Excited to share our 2 new studies published today in @TheLancetOncol — one offering deeper insight into refining #ICI for PD-L1–negative & 🧬#STK11-mutant #NSCLC, and the other exploring #ICI vs 💊#BRAF/MEKi in #BRAF V600E #NSCLC. @OncoAlert @IASLC #LCSM. /W✨@DiFedericoMD✨ These studies aren’t full answers — but we hope they help sharpen strategies and spark further progress in tailoring immunotherapy for NSCLCs historically seen as resistant. Heartfelt thanks to the co-authors, patients, collaborators & reviewers who made this possible. @marinagarassino @MarceloCorassa @peters_solange @pecci_federica1 @ACortelliniMD @dplanchard @RobertoFerrara_ @CoreyLangerMD @FawziAbuRous @mihaela_aldea @XinAnnWang @DanaFarber @DanaFarberNews @DrMarkAwad @NIVokes @StephenVLiu @NarjustFlorezMD @alessi_joao @DrJNaidoo @Alfdoc2

In an interview with @boston25, @danafarber’s @sands_jacob talks about new lung cancer treatment breakthroughs. @DFarberThoracic Watch here: bit.ly/4nw82yF